Document is current
Any future updates will be listed below
-
Authors
Lopez-Muñoz, Nieves
Bar, Noffar
Diels, Joris
van Sanden, Suzy
Mendes, João
Lee, Seina
Hernando, Teresa
Lendvai, Nikoletta
Patel, Nitin
Ishida, Tadao
Er, Jeremy
Harrison, Simon J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03548207 at ClinicalTrials.govnct04181827 at ClinicalTrials.govDocuments that mention this clinical trial
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
https://doi.org/10.1200/jco.2023.41.16_suppl.8009
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
https://doi.org/10.1200/jco.22.00842
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
https://doi.org/10.1136/jitc-2023-006684
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1200/jco-25-00760
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-025-03479-y
nct03651128 at ClinicalTrials.govDocuments that mention this clinical trial
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba106
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
https://doi.org/10.1007/s12325-025-03278-5
Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.
https://doi.org/10.1200/jco.2024.42.16_suppl.7504
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma
https://doi.org/10.1007/s12325-025-03308-2
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-025-03479-y
Documents that mention this clinical trial
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8031
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.
https://doi.org/10.1200/jco.2024.42.16_suppl.7527
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
https://doi.org/10.1200/jco.2023.41.16_suppl.8032
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
https://doi.org/10.1200/jco.2024.42.16_suppl.7529
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-025-03479-y
-
Funding
Funding for this research was provided by:
Johnson and Johnson
Legend Biotech
- License Information
-
More Information
Article History
Received: 3 October 2025
Accepted: 16 December 2025
First Online: 2 February 2026
Declarations
:
: Nieves Lopez-Muñoz: nothing to disclose. Noffar Bar: nothing to disclose. Tadao Ishida: research funding from Alexion Pharma, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Pfizer, Prothena, Sanofi, and Takeda; honoraria from Bristol-Myers Squibb, CSL Behring, Johnson & Johnson, Ono, Pfizer, Sanofi, and Takeda. Jeremy Er: nothing to disclose. Simon J Harrison: advisory board for Celgene Corporation, F. Hoffmann-La Roche AG, Genentech USA, Inc., HaemaLogiX Pty Ltd, Johnson & Johnson, and Novartis; research funding from Johnson & Johnson and HaemaLogiX Pty Ltd. Joris Diels, Suzy van Sanden, João Mendes, Seina Lee, Teresa Hernando, and Nikoletta Lendvai: employees of Johnson & Johnson and may own stock in Johnson & Johnson. Nitin Patel: an employee of Legend Biotech USA Inc and has stock and other ownership interests in Legend Biotech.
: The CARTITUDE-1, CARTITUDE-4, and KarMMa-3 trials were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for Good Clinical Practice. The protocols were approved by the ethics committee or the institutional review board (Supplementary Tables S1 and S2). All patients provided written informed consent.
